Segments of Business and Geographic Areas - Sales by Segment of Business (Details)
$ in Millions |
12 Months Ended |
|
Dec. 28, 2025
USD ($)
segment
|
Dec. 29, 2024
USD ($)
|
Dec. 31, 2023
USD ($)
|
| Segment Reporting Information [Line Items] |
|
|
|
| Number of segments | segment |
2
|
|
|
| Sales to Customers |
$ 94,193
|
$ 88,821
|
$ 85,159
|
| % Change |
6.00%
|
4.30%
|
|
| Innovative Medicine |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 60,401
|
$ 56,964
|
54,759
|
| % Change |
6.00%
|
4.00%
|
|
| Innovative Medicine | Immunology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 15,728
|
$ 17,828
|
18,052
|
| % Change |
(11.80%)
|
(1.20%)
|
|
| Innovative Medicine | Infectious Diseases |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 3,241
|
$ 3,396
|
4,418
|
| % Change |
(4.60%)
|
(23.10%)
|
|
| Innovative Medicine | Neuroscience |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 7,837
|
$ 7,115
|
7,140
|
| % Change |
10.10%
|
(0.40%)
|
|
| Innovative Medicine | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 25,380
|
$ 20,781
|
17,661
|
| % Change |
22.10%
|
17.70%
|
|
| Innovative Medicine | Pulmonary Hypertension |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 4,437
|
$ 4,282
|
3,815
|
| % Change |
3.60%
|
12.30%
|
|
| Innovative Medicine | Cardiovascular/Metabolism/Other |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 3,778
|
$ 3,562
|
3,671
|
| % Change |
6.10%
|
(3.00%)
|
|
| MedTech |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 33,792
|
$ 31,857
|
30,400
|
| % Change |
6.10%
|
4.80%
|
|
| MedTech | Cardiovascular |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 8,928
|
$ 7,707
|
6,350
|
| % Change |
15.80%
|
21.40%
|
|
| MedTech | Orthopaedics |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 9,258
|
$ 9,158
|
8,942
|
| % Change |
1.10%
|
2.40%
|
|
| MedTech | Surgery |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 10,137
|
$ 9,845
|
10,037
|
| % Change |
3.00%
|
(1.90%)
|
|
| MedTech | Vision |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 5,468
|
$ 5,146
|
5,072
|
| % Change |
6.30%
|
1.50%
|
|
| CARVYKTI | Innovative Medicine | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,887
|
$ 963
|
500
|
| % Change |
95.90%
|
92.70%
|
|
| DARZALEX | Innovative Medicine | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 14,351
|
$ 11,670
|
9,744
|
| % Change |
23.00%
|
19.80%
|
|
| ERLEADA | Innovative Medicine | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 3,574
|
$ 2,999
|
2,387
|
| % Change |
19.20%
|
25.60%
|
|
| IMBRUVICA | Innovative Medicine | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 2,823
|
$ 3,038
|
3,264
|
| % Change |
(7.10%)
|
(6.90%)
|
|
| RYBREVANT/LAZCLUZE | Innovative Medicine | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 734
|
$ 327
|
93
|
| TALVEY | Innovative Medicine | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 463
|
287
|
63
|
| % Change |
61.30%
|
|
|
| TECVAYLI | Pharmaceutical | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 670
|
$ 549
|
395
|
| % Change |
22.10%
|
38.80%
|
|
| ZYTIGA/abiraterone acetate | Innovative Medicine | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 502
|
$ 631
|
887
|
| % Change |
(20.40%)
|
(28.80%)
|
|
| Other Oncology | Innovative Medicine | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 376
|
$ 317
|
328
|
| % Change |
18.50%
|
(3.40%)
|
|
| Remicade | Innovative Medicine | Immunology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,768
|
$ 1,605
|
1,839
|
| % Change |
10.20%
|
(12.80%)
|
|
| Simponi/Simponi Aria | Innovative Medicine | Immunology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 2,668
|
$ 2,190
|
2,197
|
| % Change |
21.80%
|
(0.30%)
|
|
| Stelara | Innovative Medicine | Immunology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 6,078
|
$ 10,361
|
10,858
|
| % Change |
(41.30%)
|
(4.60%)
|
|
| Tremfya | Innovative Medicine | Immunology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 5,155
|
$ 3,670
|
3,147
|
| % Change |
40.50%
|
16.60%
|
|
| Other Immunology | Innovative Medicine | Immunology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 61
|
$ 3
|
11
|
| % Change |
|
(74.10%)
|
|
| CAPLYTA | Innovative Medicine | Neuroscience |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
700
|
$ 0
|
0
|
| % Change |
|
0.00%
|
|
| CONCERTA/Methylphenidate | Innovative Medicine | Neuroscience |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 584
|
$ 641
|
783
|
| % Change |
(9.00%)
|
(18.10%)
|
|
| INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Innovative Medicine | Neuroscience |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 3,810
|
$ 4,222
|
4,115
|
| % Change |
(9.80%)
|
2.60%
|
|
| SPRAVATO | Innovative Medicine | Neuroscience |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,696
|
$ 1,077
|
689
|
| % Change |
57.40%
|
56.40%
|
|
| OTHER NEUROSCIENCE | Innovative Medicine | Neuroscience |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,048
|
$ 1,175
|
1,553
|
| % Change |
(10.90%)
|
(24.30%)
|
|
| OPSUMIT | Innovative Medicine | Pulmonary Hypertension |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 2,325
|
$ 2,225
|
1,973
|
| % Change |
4.50%
|
12.80%
|
|
| UPTRAVI | Innovative Medicine | Pulmonary Hypertension |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,902
|
$ 1,817
|
1,582
|
| % Change |
4.70%
|
14.90%
|
|
| Other Pulmonary Hypertension | Innovative Medicine | Pulmonary Hypertension |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 209
|
$ 240
|
260
|
| % Change |
(12.70%)
|
(7.70%)
|
|
| EDURANT/rilpivirine | Innovative Medicine | Infectious Diseases |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,486
|
$ 1,272
|
1,150
|
| % Change |
16.90%
|
10.60%
|
|
| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Innovative Medicine | Infectious Diseases |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,579
|
$ 1,712
|
1,854
|
| % Change |
(7.70%)
|
(7.70%)
|
|
| Other Infectious Diseases | Innovative Medicine | Infectious Diseases |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 175
|
$ 412
|
1,414
|
| % Change |
(57.50%)
|
|
|
| XARELTO | Innovative Medicine | Cardiovascular/Metabolism/Other |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 2,633
|
$ 2,373
|
2,365
|
| % Change |
11.00%
|
0.30%
|
|
| Other | Innovative Medicine | Cardiovascular/Metabolism/Other |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,145
|
$ 1,189
|
1,306
|
| % Change |
(3.70%)
|
(8.90%)
|
|
| ELECTROPHYSIOLOGY | MedTech | Cardiovascular |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 5,634
|
$ 5,267
|
4,688
|
| % Change |
7.00%
|
12.30%
|
|
| Abiomed | MedTech | Cardiovascular |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,751
|
$ 1,496
|
1,306
|
| % Change |
17.10%
|
14.50%
|
|
| Shockwave Medical, Inc. | MedTech | Cardiovascular |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,146
|
$ 564
|
0
|
| other cardiovascular | MedTech | Cardiovascular |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 397
|
$ 380
|
356
|
| % Change |
4.30%
|
6.90%
|
|
| HIPS | MedTech | Orthopaedics |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,674
|
$ 1,638
|
1,560
|
| % Change |
2.10%
|
5.00%
|
|
| KNEES | MedTech | Orthopaedics |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,587
|
$ 1,545
|
1,456
|
| % Change |
2.70%
|
6.10%
|
|
| TRAUMA | MedTech | Orthopaedics |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 3,146
|
$ 3,049
|
2,979
|
| % Change |
3.20%
|
2.30%
|
|
| SPINE,SPORTS & OTHER | MedTech | Orthopaedics |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 2,852
|
$ 2,926
|
2,947
|
| % Change |
(2.50%)
|
(0.70%)
|
|
| ADVANCED | MedTech | Surgery |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 4,577
|
$ 4,488
|
4,671
|
| % Change |
2.00%
|
(3.90%)
|
|
| GENERAL | MedTech | Surgery |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 5,560
|
$ 5,358
|
5,366
|
| % Change |
3.80%
|
(0.20%)
|
|
| CONTACT LENSES/OTHER | MedTech | Vision |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 3,910
|
$ 3,733
|
3,702
|
| % Change |
4.80%
|
0.80%
|
|
| SURGICAL | MedTech | Vision |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,558
|
$ 1,413
|
1,370
|
| % Change |
10.20%
|
3.20%
|
|
| United States |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 53,752
|
$ 50,302
|
46,444
|
| % Change |
6.90%
|
8.30%
|
|
| United States | Innovative Medicine |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 36,344
|
$ 33,970
|
31,169
|
| % Change |
7.00%
|
9.00%
|
|
| United States | Innovative Medicine | Immunology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 9,872
|
$ 11,355
|
11,539
|
| % Change |
(13.10%)
|
(1.60%)
|
|
| United States | Innovative Medicine | Infectious Diseases |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,264
|
$ 1,354
|
1,500
|
| % Change |
(6.60%)
|
(9.80%)
|
|
| United States | Innovative Medicine | Neuroscience |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 5,151
|
$ 4,398
|
4,065
|
| % Change |
17.10%
|
8.20%
|
|
| United States | Innovative Medicine | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 13,659
|
$ 10,854
|
8,462
|
| % Change |
25.80%
|
28.30%
|
|
| United States | Innovative Medicine | Pulmonary Hypertension |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 3,223
|
$ 3,143
|
2,697
|
| % Change |
2.60%
|
16.50%
|
|
| United States | Innovative Medicine | Cardiovascular/Metabolism/Other |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 3,175
|
$ 2,866
|
2,906
|
| % Change |
10.80%
|
(1.40%)
|
|
| United States | MedTech |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 17,408
|
$ 16,332
|
15,275
|
| % Change |
6.60%
|
6.90%
|
|
| United States | MedTech | Cardiovascular |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 5,305
|
$ 4,513
|
3,633
|
| % Change |
17.50%
|
24.20%
|
|
| United States | MedTech | Orthopaedics |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 5,720
|
$ 5,689
|
5,525
|
| % Change |
0.50%
|
3.00%
|
|
| United States | MedTech | Surgery |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 4,157
|
$ 4,003
|
4,031
|
| % Change |
3.90%
|
(0.70%)
|
|
| United States | MedTech | Vision |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 2,225
|
$ 2,128
|
2,086
|
| % Change |
4.60%
|
2.00%
|
|
| United States | CARVYKTI | Innovative Medicine | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,492
|
$ 869
|
469
|
| % Change |
71.60%
|
85.20%
|
|
| United States | DARZALEX | Innovative Medicine | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 8,266
|
$ 6,588
|
5,277
|
| % Change |
25.50%
|
24.80%
|
|
| United States | ERLEADA | Innovative Medicine | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,453
|
$ 1,282
|
1,065
|
| % Change |
13.40%
|
20.30%
|
|
| United States | IMBRUVICA | Innovative Medicine | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 892
|
$ 1,020
|
1,051
|
| % Change |
(12.50%)
|
(3.00%)
|
|
| United States | RYBREVANT/LAZCLUZE | Innovative Medicine | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 534
|
$ 257
|
66
|
| United States | TALVEY | Innovative Medicine | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 340
|
241
|
56
|
| % Change |
40.90%
|
|
|
| United States | TECVAYLI | Pharmaceutical | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 444
|
$ 418
|
334
|
| % Change |
6.30%
|
25.30%
|
|
| United States | ZYTIGA/abiraterone acetate | Innovative Medicine | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 23
|
$ 34
|
50
|
| % Change |
(33.20%)
|
(32.20%)
|
|
| United States | Other Oncology | Innovative Medicine | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 214
|
$ 145
|
93
|
| % Change |
47.50%
|
55.90%
|
|
| United States | Remicade | Innovative Medicine | Immunology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,171
|
$ 1,009
|
1,143
|
| % Change |
16.00%
|
(11.70%)
|
|
| United States | Simponi/Simponi Aria | Innovative Medicine | Immunology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,193
|
$ 1,082
|
1,124
|
| % Change |
10.30%
|
(3.80%)
|
|
| United States | Stelara | Innovative Medicine | Immunology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 3,847
|
$ 6,720
|
6,966
|
| % Change |
(42.70%)
|
(3.50%)
|
|
| United States | Tremfya | Innovative Medicine | Immunology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 3,529
|
$ 2,443
|
2,147
|
| % Change |
44.50%
|
13.70%
|
|
| United States | Other Immunology | Innovative Medicine | Immunology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 59
|
$ 3
|
11
|
| % Change |
|
(74.10%)
|
|
| United States | CAPLYTA | Innovative Medicine | Neuroscience |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
700
|
$ 0
|
0
|
| % Change |
|
0.00%
|
|
| United States | CONCERTA/Methylphenidate | Innovative Medicine | Neuroscience |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 82
|
$ 134
|
230
|
| % Change |
(38.60%)
|
(41.70%)
|
|
| United States | INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Innovative Medicine | Neuroscience |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 2,725
|
$ 3,125
|
2,897
|
| % Change |
(12.80%)
|
7.90%
|
|
| United States | SPRAVATO | Innovative Medicine | Neuroscience |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,485
|
$ 929
|
589
|
| % Change |
59.90%
|
57.80%
|
|
| United States | OTHER NEUROSCIENCE | Innovative Medicine | Neuroscience |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 159
|
$ 210
|
349
|
| % Change |
(24.50%)
|
(39.80%)
|
|
| United States | OPSUMIT | Innovative Medicine | Pulmonary Hypertension |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,633
|
$ 1,557
|
1,292
|
| % Change |
4.80%
|
20.50%
|
|
| United States | UPTRAVI | Innovative Medicine | Pulmonary Hypertension |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,536
|
$ 1,511
|
1,326
|
| % Change |
1.70%
|
13.90%
|
|
| United States | Other Pulmonary Hypertension | Innovative Medicine | Pulmonary Hypertension |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 54
|
$ 75
|
79
|
| % Change |
(27.00%)
|
(5.10%)
|
|
| United States | EDURANT/rilpivirine | Innovative Medicine | Infectious Diseases |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 26
|
$ 31
|
35
|
| % Change |
(18.40%)
|
(10.00%)
|
|
| United States | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Innovative Medicine | Infectious Diseases |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,226
|
$ 1,311
|
1,446
|
| % Change |
(6.50%)
|
(9.40%)
|
|
| United States | Other Infectious Diseases | Innovative Medicine | Infectious Diseases |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 12
|
$ 11
|
19
|
| % Change |
6.60%
|
(41.00%)
|
|
| United States | XARELTO | Innovative Medicine | Cardiovascular/Metabolism/Other |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 2,633
|
$ 2,373
|
2,365
|
| % Change |
11.00%
|
0.30%
|
|
| United States | Other | Innovative Medicine | Cardiovascular/Metabolism/Other |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 542
|
$ 494
|
541
|
| % Change |
9.80%
|
(8.80%)
|
|
| United States | ELECTROPHYSIOLOGY | MedTech | Cardiovascular |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 2,891
|
$ 2,738
|
2,458
|
| % Change |
5.60%
|
11.40%
|
|
| United States | Abiomed | MedTech | Cardiovascular |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,393
|
$ 1,213
|
1,066
|
| % Change |
14.90%
|
13.70%
|
|
| United States | Shockwave Medical, Inc. | MedTech | Cardiovascular |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 897
|
$ 442
|
0
|
| United States | other cardiovascular | MedTech | Cardiovascular |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 124
|
$ 120
|
109
|
| % Change |
3.10%
|
10.70%
|
|
| United States | HIPS | MedTech | Orthopaedics |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,080
|
$ 1,057
|
996
|
| % Change |
2.10%
|
6.20%
|
|
| United States | KNEES | MedTech | Orthopaedics |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 924
|
$ 922
|
896
|
| % Change |
0.20%
|
2.90%
|
|
| United States | TRAUMA | MedTech | Orthopaedics |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 2,058
|
$ 2,013
|
1,949
|
| % Change |
2.20%
|
3.30%
|
|
| United States | SPINE,SPORTS & OTHER | MedTech | Orthopaedics |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,658
|
$ 1,696
|
1,684
|
| % Change |
(2.20%)
|
0.70%
|
|
| United States | ADVANCED | MedTech | Surgery |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,900
|
$ 1,838
|
1,833
|
| % Change |
3.40%
|
0.20%
|
|
| United States | GENERAL | MedTech | Surgery |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 2,258
|
$ 2,165
|
2,198
|
| % Change |
4.30%
|
(1.50%)
|
|
| United States | CONTACT LENSES/OTHER | MedTech | Vision |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,754
|
$ 1,684
|
1,626
|
| % Change |
4.10%
|
3.60%
|
|
| United States | SURGICAL | MedTech | Vision |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 471
|
$ 444
|
460
|
| % Change |
6.10%
|
(3.40%)
|
|
| Non-US |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 40,441
|
$ 38,519
|
38,715
|
| % Change |
5.00%
|
(0.50%)
|
|
| Non-US | Innovative Medicine |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 24,057
|
$ 22,994
|
23,590
|
| % Change |
4.60%
|
(2.50%)
|
|
| Non-US | Innovative Medicine | Immunology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 5,856
|
$ 6,473
|
6,513
|
| % Change |
(9.50%)
|
(0.60%)
|
|
| Non-US | Innovative Medicine | Infectious Diseases |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,977
|
$ 2,042
|
2,918
|
| % Change |
(3.20%)
|
(30.00%)
|
|
| Non-US | Innovative Medicine | Neuroscience |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 2,686
|
$ 2,718
|
3,076
|
| % Change |
(1.20%)
|
(11.60%)
|
|
| Non-US | Innovative Medicine | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 11,721
|
$ 9,926
|
9,199
|
| % Change |
18.10%
|
7.90%
|
|
| Non-US | Innovative Medicine | Pulmonary Hypertension |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,214
|
$ 1,140
|
1,117
|
| % Change |
6.50%
|
2.00%
|
|
| Non-US | Innovative Medicine | Cardiovascular/Metabolism/Other |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 603
|
$ 696
|
765
|
| % Change |
(13.30%)
|
(9.10%)
|
|
| Non-US | MedTech |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 16,384
|
$ 15,525
|
15,125
|
| % Change |
5.50%
|
2.60%
|
|
| Non-US | MedTech | Cardiovascular |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 3,623
|
$ 3,194
|
2,717
|
| % Change |
13.40%
|
17.60%
|
|
| Non-US | MedTech | Orthopaedics |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 3,538
|
$ 3,470
|
3,417
|
| % Change |
2.00%
|
1.50%
|
|
| Non-US | MedTech | Surgery |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 5,980
|
$ 5,842
|
6,006
|
| % Change |
2.40%
|
(2.70%)
|
|
| Non-US | MedTech | Vision |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 3,243
|
$ 3,018
|
2,986
|
| % Change |
7.40%
|
1.10%
|
|
| Non-US | CARVYKTI | Innovative Medicine | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 395
|
$ 94
|
30
|
| Non-US | DARZALEX | Innovative Medicine | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 6,085
|
$ 5,082
|
4,467
|
| % Change |
19.70%
|
13.80%
|
|
| Non-US | ERLEADA | Innovative Medicine | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 2,121
|
$ 1,717
|
1,322
|
| % Change |
23.50%
|
29.80%
|
|
| Non-US | IMBRUVICA | Innovative Medicine | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,931
|
$ 2,018
|
2,214
|
| % Change |
(4.30%)
|
(8.80%)
|
|
| Non-US | RYBREVANT/LAZCLUZE | Innovative Medicine | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 200
|
$ 70
|
27
|
| Non-US | TALVEY | Innovative Medicine | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
123
|
46
|
7
|
| Non-US | TECVAYLI | Pharmaceutical | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 226
|
131
|
61
|
| % Change |
72.80%
|
|
|
| Non-US | ZYTIGA/abiraterone acetate | Innovative Medicine | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 480
|
$ 597
|
837
|
| % Change |
(19.70%)
|
(28.60%)
|
|
| Non-US | Other Oncology | Innovative Medicine | Oncology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 162
|
$ 172
|
235
|
| % Change |
(6.00%)
|
(26.80%)
|
|
| Non-US | Remicade | Innovative Medicine | Immunology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 523
|
$ 497
|
549
|
| % Change |
5.30%
|
(9.50%)
|
|
| Non-US | Simponi/Simponi Aria | Innovative Medicine | Immunology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,475
|
$ 1,108
|
1,073
|
| % Change |
33.10%
|
3.30%
|
|
| Non-US | Stelara | Innovative Medicine | Immunology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 2,230
|
$ 3,641
|
3,892
|
| % Change |
(38.70%)
|
(6.40%)
|
|
| Non-US | Tremfya | Innovative Medicine | Immunology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,626
|
$ 1,227
|
999
|
| % Change |
32.50%
|
22.80%
|
|
| Non-US | Other Immunology | Innovative Medicine | Immunology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 2
|
$ 0
|
0
|
| % Change |
|
0.00%
|
|
| Non-US | CAPLYTA | Innovative Medicine | Neuroscience |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 0
|
$ 0
|
0
|
| % Change |
0.00%
|
0.00%
|
|
| Non-US | CONCERTA/Methylphenidate | Innovative Medicine | Neuroscience |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 502
|
$ 507
|
554
|
| % Change |
(1.20%)
|
(8.40%)
|
|
| Non-US | INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Innovative Medicine | Neuroscience |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,085
|
$ 1,097
|
1,218
|
| % Change |
(1.10%)
|
(9.90%)
|
|
| Non-US | SPRAVATO | Innovative Medicine | Neuroscience |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 210
|
$ 148
|
100
|
| % Change |
41.90%
|
48.20%
|
|
| Non-US | OTHER NEUROSCIENCE | Innovative Medicine | Neuroscience |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 889
|
$ 965
|
1,204
|
| % Change |
(7.90%)
|
(19.80%)
|
|
| Non-US | OPSUMIT | Innovative Medicine | Pulmonary Hypertension |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 692
|
$ 668
|
681
|
| % Change |
3.70%
|
(1.90%)
|
|
| Non-US | UPTRAVI | Innovative Medicine | Pulmonary Hypertension |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 366
|
$ 307
|
255
|
| % Change |
19.40%
|
20.10%
|
|
| Non-US | Other Pulmonary Hypertension | Innovative Medicine | Pulmonary Hypertension |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 155
|
$ 165
|
182
|
| % Change |
(6.20%)
|
(9.30%)
|
|
| Non-US | EDURANT/rilpivirine | Innovative Medicine | Infectious Diseases |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,461
|
$ 1,241
|
1,115
|
| % Change |
17.70%
|
11.20%
|
|
| Non-US | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Innovative Medicine | Infectious Diseases |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 353
|
$ 401
|
408
|
| % Change |
(11.90%)
|
(1.70%)
|
|
| Non-US | Other Infectious Diseases | Innovative Medicine | Infectious Diseases |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 163
|
$ 401
|
1,395
|
| % Change |
(59.30%)
|
|
|
| Non-US | XARELTO | Innovative Medicine | Cardiovascular/Metabolism/Other |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 0
|
$ 0
|
0
|
| % Change |
0.00%
|
0.00%
|
|
| Non-US | Other | Innovative Medicine | Cardiovascular/Metabolism/Other |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 603
|
$ 696
|
765
|
| % Change |
(13.30%)
|
(9.10%)
|
|
| Non-US | ELECTROPHYSIOLOGY | MedTech | Cardiovascular |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 2,743
|
$ 2,529
|
2,230
|
| % Change |
8.50%
|
13.40%
|
|
| Non-US | Abiomed | MedTech | Cardiovascular |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 358
|
$ 284
|
240
|
| % Change |
26.40%
|
18.20%
|
|
| Non-US | Shockwave Medical, Inc. | MedTech | Cardiovascular |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 249
|
$ 122
|
0
|
| Non-US | other cardiovascular | MedTech | Cardiovascular |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 273
|
$ 260
|
247
|
| % Change |
4.90%
|
5.30%
|
|
| Non-US | HIPS | MedTech | Orthopaedics |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 594
|
$ 581
|
564
|
| % Change |
2.20%
|
3.00%
|
|
| Non-US | KNEES | MedTech | Orthopaedics |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 663
|
$ 623
|
559
|
| % Change |
6.50%
|
11.30%
|
|
| Non-US | TRAUMA | MedTech | Orthopaedics |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,088
|
$ 1,036
|
1,030
|
| % Change |
5.00%
|
0.60%
|
|
| Non-US | SPINE,SPORTS & OTHER | MedTech | Orthopaedics |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,193
|
$ 1,230
|
1,263
|
| % Change |
(3.00%)
|
(2.60%)
|
|
| Non-US | ADVANCED | MedTech | Surgery |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 2,678
|
$ 2,650
|
2,837
|
| % Change |
1.00%
|
(6.60%)
|
|
| Non-US | GENERAL | MedTech | Surgery |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 3,302
|
$ 3,192
|
3,168
|
| % Change |
3.40%
|
0.80%
|
|
| Non-US | CONTACT LENSES/OTHER | MedTech | Vision |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 2,157
|
$ 2,049
|
2,076
|
| % Change |
5.30%
|
(1.30%)
|
|
| Non-US | SURGICAL | MedTech | Vision |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 1,086
|
$ 969
|
910
|
| % Change |
12.10%
|
6.50%
|
|
| UNITED STATES Exports | Remicade | Innovative Medicine | Immunology |
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
| Sales to Customers |
$ 74
|
$ 98
|
$ 147
|
| % Change |
(24.80%)
|
(33.00%)
|
|